Detail akcie Circassia online

Business Summary: NIOX Group plc is a United Kingdom-based diagnostics and management company. The Company is engaged in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNO), a precise biomarker for asthma. The Company's NIOX VERO is also the device of choice by clinical research organizations for respiratory studies. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company provides products and services via its direct sales organization and extensive distributor network in over 50 countries.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Niox Group PLC revenues increased 20% to L25.2M. Net income increased 34% to L5.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from operating-NIOX segment income increase of 26% to L7.7M. Basic Earnings per Share excluding Extraordinary Items remained flat at L0.01.